HUM vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

HUM

58.5
AI Score
VS
HUM Wins

CLOV

33.5
AI Score

Investment Advisor Scores

HUM

59score
Recommendation
BUY

CLOV

34score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric HUM CLOV Winner
Forward P/E 24.3309 37.7358 HUM
PEG Ratio 1.2545 0 Tie
Revenue Growth 26.2% 55.6% CLOV
Earnings Growth 27.1% 0.0% HUM
Tradestie Score 58.5/100 33.5/100 HUM
Profit Margin 0.9% -0.7% HUM
Beta 1.00 1.00 Tie
AI Recommendation BUY AVOID NEW MONEY HUM

Relative Price Performance (Last 90 Days)

HUM 1M: -3.1% · 3M: -1.1% CLOV 1M: +1.9% · 3M: -13.4%

Current Technical Phase

HUM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $388.36

CLOV

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -3.2%) with fading momentum, RSI 48

RSI (14): 47.6 · Price: $4.38

Fundamentals Snapshot

Metric HUM CLOV
Market Cap — —
Forward P/E 23.4 29.2
Trailing P/E 35.9 —
Revenue (TTM) — —
Revenue Growth 0.3% 0.6%
Gross Margin 0.1% 0.2%
Operating Margin 0.0% 0.0%
EPS 10.57 -0.05
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, HUM is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.